Free Trial
NASDAQ:SRZN

Surrozen Q4 2024 Earnings Report

Surrozen logo
$8.46 -0.02 (-0.29%)
As of 05/30/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Surrozen EPS Results

Actual EPS
-$9.10
Consensus EPS
-$2.54
Beat/Miss
Missed by -$6.56
One Year Ago EPS
N/A

Surrozen Revenue Results

Actual Revenue
$0.66 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Surrozen Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, March 31, 2025
Conference Call Time
3:00PM ET

Upcoming Earnings

Surrozen's Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Surrozen Earnings Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
Surrozen files to sell 5.21M shares of common stock for holders
See More Surrozen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Surrozen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Surrozen and other key companies, straight to your email.

About Surrozen

Surrozen (NASDAQ:SRZN), a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

View Surrozen Profile

More Earnings Resources from MarketBeat